Sacubitril-Valsartan Market

The Sacubitril-Valsartan market is projected to grow at a CAGR of 7.1% from 2025 to 2035, driven by the rising global burden of heart failure, growing clinical adoption of novel therapies with mortality benefits, and increasing guideline recommendations supporting its use as a first-line agent in heart failure with reduced ejection fraction (HFrEF). Sacubitril-Valsartan is a combination drug consisting of a neprilysin inhibitor (Sacubitril) and an angiotensin receptor blocker (Valsartan). This dual mechanism enhances natriuretic peptides while blocking the renin-angiotensin system, thereby reducing blood pressure, improving cardiac output, and lowering hospitalization and mortality rates.

Approved under the brand name Entresto, Sacubitril-Valsartan has revolutionized heart failure management, particularly for patients with HFrEF. Ongoing clinical trials are also exploring its utility in heart failure with preserved ejection fraction (HFpEF) and other cardiovascular conditions such as hypertension and post-myocardial infarction cardiac remodeling. Increasing awareness of heart failure guidelines (ACC/AHA, ESC), rising patient compliance due to once-daily dosing, and favorable real-world evidence of improved outcomes are propelling demand.

North America leads the Sacubitril-Valsartan market due to high cardiovascular disease prevalence, well-established healthcare reimbursement systems, and rapid uptake of guideline-directed therapies. Europe shows robust growth driven by aging populations and proactive heart failure programs. The Asia-Pacific region is expected to register the fastest CAGR, attributed to rising incidence of heart failure, improving access to cardiovascular drugs, and expanding clinical trial activity. Latin America and Africa show gradual growth due to increasing diagnosis rates and public health efforts in managing chronic cardiac conditions.